

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

03 AUG 14 PM 4: 54

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The Livingston Group, L.L.C.			
2. Address <input type="checkbox"/> Check if different than previously reported 499 S. Capitol Street, S.W. Suite 600 Washington, DC 20003			
3. Principal Place of Business (if different from line 2) City: _____ State/zip (or Country) _____			
4. Contact Name Robert L. Livingston	Telephone (202) 289-9881	E-mail (optional)	5. Senate ID # 49635-1255
7. Client Name <input type="checkbox"/> Self The PKD Foundation			6. House ID # 34606-086

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30)  OR Year End (July 1-December) 
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_11. No Lobbying Activities **INCOME OR EXPENSES** Complete Either Line 12 OR Line 13

<p align="center"><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>40,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b) of Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of Internal Revenue Code</p>
--	--

Signature \_\_\_\_\_

Date \_\_\_\_\_

Printed Name and Title

ROBERT L. LIVINGSTON, President

LD-2 (REV. 4/03)

PAGE 1 of —

Registrant Name The Livingston Group, L.L.C. Client Name The PKD Foundation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

HHS Appropriations for research and clinical funding (HR 2660; S 1356);


17. House(s) of Congress and Federal agencies contacted  Check if None

House, Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Vicki E. Hart	
Robert L. Livingston	
Russell J. Mueller	
Susan Ramthun	
Allison DeKosky	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date \_\_\_\_\_  
Printed Name and Title Robert L. Livingston, President



Registrant Name The Livingston Group, L.L.C. Client Name The PKD Foundation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

HHS Appropriations for research and clinical funding (HR 2660; S 1356); Medicare Immunosuppressive drug legislation (HR 1; S 1).


17. House(s) of Congress and Federal agencies contacted  Check if None

House, Senate, HHS.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Vicki E. Hart	
Robert L. Livingston	
Russell J. Mueller	
Susan Ramthun	
Allison DeKosky	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date \_\_\_\_\_  
Printed Name and Title Robert L. Livingston, President



Registrant Name The Livingston Group, L.L.C. Client Name The PKD Foundation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Immunosuppressive drug legislation (HR 1; S 1).


17. House(s) of Congress and Federal agencies contacted  Check if None

House, Senate, HHS.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Vicki E. Hart	
Robert L. Livingston	
Russell J. Mueller	
Susan Ramthun	
Allison DeKosky	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date \_\_\_\_\_  
Printed Name and Title Robert L. Livingston, President

/

Registrant Name The Livingston Group, L.L.C. Client Name The PKD Foundation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Medicare Immunosuppressive drug legislation (HR 1; S 1); HHS Appropriations for research and clinical funding (HR 2660; S 1356).


17. House(s) of Congress and Federal agencies contacted  Check if None

House, Senate, HHS.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Vicki E. Hart	
Robert L. Livingston	
Russell J. Mueller	
Susan Ramthun	
Allison DeKosky	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 8/14/03

Printed Name and Title Robert L. Livingston, President

